Navigation Links
Exelixis Announces February 12 Webcast of Presentation at the 10th Annual BIO CEO and Investor Conference
Date:2/6/2008

SOUTH SAN FRANCISCO, Calif., Feb. 6 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that George A. Scangos, Ph.D., president and chief executive officer of Exelixis, will present at the 10th Annual BIO CEO and Investor Conference at 2:45 p.m. ET / 11:45 a.m. PT on Tuesday, February 12, 2008.

The presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at http://www.exelixis.com.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
2. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
3. Exelixis Announces Closing of Public Offering of Common Stock
4. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
5. Exelixis Announces November 5 Webcast of its 2007 Third Quarter Financial Results Conference Call
6. Exelixis Announces Third Quarter 2007 Financial Results and Business Update
7. Exelixis Sells 80% Stake in Artemis to Taconic
8. Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
9. Exelixis Announces November 27 Webcast of Presentation at the 19th Annual Piper Jaffray Health Care Conference
10. Exelixis Announces November 28 Webcast of Presentation at the Lazard Capital Markets Fourth Annual Healthcare Conference
11. Reminder: Exelixis Announces December 5 Webcast of Its Third Annual R&D Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
(Date:7/10/2014)... July 10, 2014 EvoDerma ’s NOOME ... This rejuvenating device now comes with a second treatment cup ... time. , The new cup is thinner on the edges ... to target rough, thin and uneven surfaces on the face, ... for a stimulating treatment on areas such as the cheeks ...
(Date:7/10/2014)... 2014 On July 9 Prime ... presented Russia,s first national "Industry" ... Company is developing a unique project called MabNext ... a number of innovative drugs based on monoclonal antibodies ... took place at the International Exhibition "Innoprom 2014" in ...
(Date:7/10/2014)... July 10, 2014 Research and Markets ... the "International Photonic Integrated Circuit (Monolithic Integration, ... 2019" report to their offering. ... concept of photonic integration traces its roots in ... promise of photonic integration went unexplored and unfulfilled ...
Breaking Biology Technology:Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... database to explore, understand, manage, and share next-generation ... Inc., the leader in sequence data management, today ... Expression Workflow designed to enable researchers working with ... is the second such workflow to be delivered ...
... May 5 Sequella, Inc., a clinical-stage biopharmaceutical company ... start of its Phase 1B trial for SQ109 with ... a new diamine antibiotic intended to replace one or ... patient therapy, was granted U.S. FDA Fast Track designation ...
... influenza virus-like particle (VLP) vaccine progresses with study designed ... May 5 Novavax, Inc. (Nasdaq: NVAX ... second clinical trial of its virus-like particle (VLP) seasonal ... this Phase II randomized, placebo controlled clinical trial has ...
Cached Biology Technology:GenomeQuest, Inc. Announces Digital Gene Expression Solution Within Its Sequence Data Management Platform 2Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109 2Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 2Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 3Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate 4
(Date:7/11/2014)... 2014 Research and Markets has ... Market - Industry Analysis Size Share Growth Trends and ... http://photos.prnewswire.com/prnh/20130307/600769 The ... a need for high level security in both private ... such as username and passwords, tokens etc. are vulnerable ...
(Date:7/10/2014)... 2014  The American Academy of Forensic Sciences ... and Technology (NIST) and the Department of Justice ... forensic science expert members to the Forensic Science ... of the NIST,s Organization of Scientific Area Committees ... appointments made to the new FSSB that has ...
(Date:7/10/2014)... BLUE BELL, Pa. , July 2, 2014  Unisys ... The Netherlands , Unisys Nederland N.V., today announced that ... (DJI) to deliver, implement and manage a new Basic Provision ... . Unisys won the contract with a ... for identity management software. The term of the contract is ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
... its wood and cottony fibers, the kapok tree now ... for decades: the notion that African and South American ... million years ago. , Research by University of Michigan ... perhaps other rainforest--trees colonized Africa after the continents split ...
... modification to successfully manipulate the growth in height of trees, ... similar to normal trees – but after several years of ... few inches. , This is a “proof of concept” that ... It opens the door to a wide variety of new ...
... that will be published online in advance of its July ... colleagues (The Salk Institute and HHMI) demonstrate that endosomes can ... animals. , "These findings will influence our thinking of the ... why cells use them as signaling compartments," noted lead author ...
Cached Biology News:The kapok connection -- Study explains rainforest similarities 2Researchers demonstrate way to control tree height 2Researchers demonstrate way to control tree height 3
... tissue extracts (liver, kidney, spleen, and heart) and ... It was also tested with microsomal fractions prepared ... simple and reliable method for measuring NDPase activity ... the inorganic phosphate released from NDP by the ...
... CAST Equine EIA Principle: ... LTD4 and LTE4 are products ... 5-lipoxygenase and glutathione-S-transferase. In the ... "Slow Reacting Substances of Anaphylaxis ...
... stress is the condition in which a ... stimuli and the various antioxidants. Oxidative ... pathogenesis of several diseases, including artherosclerosis, chronic ... possesses several antioxidant systems that are very ...
... Compound(s) tested through ... enzyme assays spanning a ... assay panel includes many ... and several non-selective assays. ...
Biology Products: